stonks4u
Sign up free
ARMP logo

ARMP Armata Pharmaceuticals, Inc.

New York Stock Exchange Arca · Biotechnology · Healthcare

$4.56
-0.26 (-5.39%)

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline …

Market Cap: $167.40Mwww.armatapharma.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 12Aug 12

Quote

Day Range
$4.42 – $4.79
52-Week Range
$2.40 – $16.34
Volume
$110.5K
Market Cap
$167.40M
50-Day Avg
$5.63
200-Day Avg
$7.55
Prev Close
$4.82
Open
$4.79

Valuation & Ratios

P/E Ratio
-1.31
EPS
$-4.80
P/B Ratio
-1.04
P/S Ratio
46.41
Debt/Equity
-1.32
Current Ratio
1.19
Dividend Yield
+0.0%
Gross Margin
+68.8%

Returns & Efficiency

Return on Equity
+79.5%
Return on Assets
-226.1%
FCF Yield
-11.6%
EV/EBITDA
-3.26

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$4.90M$-173.80M$-4.80
2024$5.17M$-18.92M$-0.52
2023$4.53M$-69.05M$-1.91
2022$5.51M$-36.92M$-1.08
2021$4.47M$-23.16M$-0.96

Social Signal Score

50
5d
50
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.41 per share

5of 7 quarters beat consensus

Typical surprise +17.9% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.27 vs $-0.45beat
  • Wed, May 13$-3.16 vs $-0.38miss
  • Wed, Mar 25$-0.51 vs $-0.19miss
  • Wed, Nov 12$-0.42 vs $-0.42beat
  • Tue, Aug 12$-0.32 vs $-0.39beat
  • Wed, May 14$-0.20 vs $-0.38beat

Estimates and results for ARMP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ARMPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsprnewswire.com·2d ago·Neutral

    Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update LOS ANGELES, Aug. 12, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its secon

    View source ↗